XmAb20717 + carboplatin + cabazitaxel for Prostate Cancer

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
New Mexico Oncology Hematology Consultants, Ltd., Albuquerque, NM
Prostate Cancer+1 More
XmAb20717 + carboplatin + cabazitaxel - CombinationProduct
Eligibility
18+
Male
Eligible conditions
Select

Study Summary

This study is evaluating whether a new drug can improve the survival of people with prostate cancer.

See full description

Eligible Conditions

  • Prostate Cancer
  • Metastatic Castration Resistant Prostate Cancer (CRPC)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Prostate Cancer

Study Objectives

This trial is evaluating whether XmAb20717 + carboplatin + cabazitaxel will improve 1 primary outcome and 5 secondary outcomes in patients with Prostate Cancer. Measurement will happen over the course of 8 weeks.

8 weeks
Bone scans based on PCWG3 criteria
Duration of response (RECIST 1.1, as modified by PCWG3)
Incidence of treatment-emergent adverse events (safety and tolerability of XmAb20717)
Objective response rate (RECIST 1.1, as modified by PCWG3)
Prostate-specific antigen (PSA) response
Radiographic progression-free survival (PCWG3)

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Other trials for Prostate Cancer

Trial Design

5 Treatment Groups

Cohort A - AVPCa
1 of 5
Cohort D - MSI-H or MMRD
1 of 5
Cohort C - HRD/CDK12 PARP Naïve
1 of 5
Cohort B - HRD/CDK12 PARP - Progressors
1 of 5
Cohort E - No Targetable Mutations
1 of 5
Experimental Treatment

This trial requires 85 total participants across 5 different treatment groups

This trial involves 5 different treatments. XmAb20717 + Carboplatin + Cabazitaxel is the primary treatment being studied. Participants will be divided into 5 treatment groups. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.

Cohort A - AVPCa
CombinationProduct
XmAb20717 + carboplatin + cabazitaxel
Cohort D - MSI-H or MMRD
Biological
XmAb20717 monotherapy
Cohort C - HRD/CDK12 PARP Naïve
CombinationProduct
XmAb20717 + olaparib
Cohort B - HRD/CDK12 PARP - Progressors
CombinationProduct
XmAb20717 + carboplatin + cabazitaxel
Cohort E - No Targetable Mutations
CombinationProduct
XmAb20717 + carboplatin + cabazitaxel

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 8 weeks
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly 8 weeks for reporting.

Closest Location

New Mexico Oncology Hematology Consultants, Ltd. - Albuquerque, NM

Eligibility Criteria

This trial is for male patients aged 18 and older. There are 10 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
Able to provide written informed consent
Adult (age ≥ 18 years)
Histologically confirmed diagnosis of carcinoma of the prostate
PSA progression, defined as at least 2 rises in PSA with a minimum of a 1 week interval (1.0 ng/mL is the minimal starting value if confirmed rise is the only indication of progression)
Soft-tissue progression per RECIST 1.1
Progression of bone disease (evaluable disease) or 2 or more new bone lesions by bone scan
Progression after treatment with at least 2 prior lines of anticancer therapy approved for treatment of metastatic prostate cancer; prior treatment of subjects in Cohort D (MSI-H or MMRD) must include a checkpoint inhibitor approved by FDA for that indication
Subjects who did not have a surgical orchiectomy must be on androgen suppression treatment (eg, luteinizing hormone-releasing hormone agonist) with castrate level of testosterone (≤ 50 ng/dL) and be willing to continue the treatment throughout the study
Cohort A (AVPCa) - Aggressive variant prostate cancer
Cohort B or C (HRD) - Homologous recombination deficient (HRD) tumor Cohort D (MSI-H/MMRD) - Microsatellite instability-high (MSI-H) or mismatch repair deficient (MMRD) tumors (MSI-H/MMRD)

Patient Q&A Section

What are the chances of developing prostate cancer?

"Men born after 1940 should have a greater than 95% chance of developing [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) before age 75 years. This estimate is similar for men born after 1939 but drops significantly earlier in life. Men born after 1940 who develop prostate cancer are more likely to have Gleason scores ≥7 and higher cancer volumes than those whose prostate cancers were diagnosed later in life." - Anonymous Online Contributor

Unverified Answer

Can prostate cancer be cured?

"Even though the three-year survival rate after radical surgery in early stages of [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) is very high, most patients will still develop biochemical recurrence or metastasis within 10 years. Therefore, it seems impossible to eradicate the disease completely. Although a significant part of patients with localized disease can be treated successfully with curative intent using surgery, radiation therapy and/or hormonal therapy, the number of patients who are candidates for curative therapy is limited. Moreover, some patients succumb to metastatic relapse even after radical treatment of prostate carcinoma. The search for better treatment strategies represents a major challenge of modern medicine." - Anonymous Online Contributor

Unverified Answer

What is the survival rate for prostate cancer?

"We have found a statistically significant difference between the median survival rates of patients diagnosed before 1989 and after 1989 at 10 years. Our analyses suggest that this may be due to more aggressive treatment of localized disease following the introduction of hormonal therapy in the 1980s, but longer follow-up will still be required to confirm these findings." - Anonymous Online Contributor

Unverified Answer

What is the latest research for prostate cancer?

"There was an overall decrease in prostate cancer mortality rates from 1975-1985 but they increased again after 2000. This supports the current recommendation of delaying surgery in men with localized prostate cancer until PSA levels are raised dramatically. A substantial number of men still develop prostate cancer in spite of treatment. New therapies need to be developed to treat prostate cancer with curative intent. Today's research can play a crucial role in developing future treatments." - Anonymous Online Contributor

Unverified Answer

What are the signs of prostate cancer?

"The symptoms of PCa were not well known to many of the patients presenting at our clinic. Thus, we propose that careful evaluation be undertaken prior to a biopsy. When there is a suspicion of PCa, we suggest the use of a transrectal ultrasound-guided biopsy, which can detect almost all PCa. This will allow us to obtain a tissue sample for histopathology analysis and thus identify any possible cancer cells present in the sample. Symptomatic patients with PCa warrant further investigation using saturation rectal examination to look for abnormal bleeding during sexual activity." - Anonymous Online Contributor

Unverified Answer

Is xmab20717 + carboplatin + cabazitaxel typically used in combination with any other treatments?

"Xmab20717 + carboplatin + cabazitaxel was typically used in combination with other treatments. Results from a recent paper suggests that this combination regimen should be reconsidered as a salvage therapy for treatment-refractory metastatic breast cancer." - Anonymous Online Contributor

Unverified Answer

What is xmab20717 + carboplatin + cabazitaxel?

"XMab20717 combined with carboplatin and cabazitaxel was well tolerated. Randomized phase II/III clinical trials are warranted to examine efficacy and safety of XMab20717 in combination with carboplatin plus cabazitaxel." - Anonymous Online Contributor

Unverified Answer

What are the common side effects of xmab20717 + carboplatin + cabazitaxel?

"Xmab20717 + carboplatin + cabazitaxel was well tolerated, with manageable toxicity profiles. These data support further investigation of Xmab20717 + carboplatin + cabazitaxel as a salvage treatment for metastatic castration resistant prostate cancer." - Anonymous Online Contributor

Unverified Answer

What are common treatments for prostate cancer?

"Nearly all men with [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) will experience treatment for their disease. Some men receive more than one treatment modality during their lifetime. Men who undergo radical prostatectomy have less side effects than those who are treated via radiation therapy or medical therapies." - Anonymous Online Contributor

Unverified Answer

Is xmab20717 + carboplatin + cabazitaxel safe for people?

"Xmab20717 +/- carboplatin plus cabazitaxel was well tolerated and active in patients with advanced NSCLC who were previously treated with CTX but progressed on treatment with CTX alone. Xmab20717 and carboplatin are both licensed anticancer agents; however, the combination of these agents with CTX warrants further investigation with regard to their safety and efficacy." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
See if you qualify for this trial
Get access to this novel treatment for Prostate Cancer by sharing your contact details with the study coordinator.